Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

11/14/24 2:05:25 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CLDI alert in real time by email

SC 13G/A 1 Calidi.txt CALIDI BIOTHERAPEUTICS, INC. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No._3)* (Name of Issuer) Calidi Biotherapeutics, Inc. (Title of Class of Securities) Common stock, par value $0.0001 per share (CUSIP Number) 320703309 (Date of Event Which Requires Filing of this Statement) 09/30/2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 320703309 (1) Names of reporting persons Polar Asset Management Partners Inc. (2) Check the appropriate box if a member of a group (see instructions) (a) (b) (3) SEC use only (4) Citizenship or place of organization Ontario, Canada Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power (7) Sole dispositive power 0 (8) Shared dispositive power (9) Aggregate amount beneficially owned by each reporting person 0 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 0.0% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Calidi Biotherapeutics, Inc. Item 1(b) Address of issuer's principal executive offices: 437 MADISON AVENUE, 27TH FLOOR, NEW YORK, NY, 10022 2(a) Name of person filing: This statement is filed by Polar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada, which serves as the investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company ("PMSMF") with respect to the shares directly held by PMSMF. 2(b) Address or principal business office or, if none, residence: 16 York Street, Suite 2900, Toronto, ON, Canada M5J 0E6. 2(c) Citizenship: Canada 2(d) Title of class of securities: Common stock, par value $0.0001 per share 2(e) CUSIP Number: 320703309 Item 3. [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); [x] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: The Reporting Person is an investment fund manager, portfolio manager, exempt market dealer and commodity trading manager registered with the Ontario Securities Commission. Item 4. Ownership as of September 30th 2024 1. Polar Asset Management Partners Inc. (a) Amount beneficially owned: 0 (b) Percent of class: 0.0% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X]. Instruction. Dissolution of a group requires a response to this item. Not applicable Item 6. Ownership of More than 5 Percent on Behalf of Another Person. Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 14, 2024 POLAR ASSET MANAGEMENT PARTNERS INC. By: /s/ Andrew Ma Name: Andrew Ma Title: Chief Compliance Officer

Get the next $CLDI alert in real time by email

Date

Price Target

Rating

Analyst

11/22/2023

$11.00

Buy

H.C. Wainwright

10/9/2023

$9.00

Outperform

Robert W. Baird

Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

Chat with this insight

Recent Analyst Ratings for
$CLDI

$CLDI
Press Releases

Fastest customizable press release news feed in the world

Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

$CLDI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

$CLDI
Financials

Live finance-specific insights

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

$CLDI
SEC Filings

SEC Form DEFA14A filed by Calidi Biotherapeutics Inc.

SEC Form DEF 14A filed by Calidi Biotherapeutics Inc.

SEC Form SCHEDULE 13G filed by Calidi Biotherapeutics Inc.

$CLDI
Leadership Updates

Live Leadership Updates

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

$CLDI
Large Ownership Changes

This live feed shows all institutional transactions in real time.